9 November 2001
Source: http://www.access.gpo.gov/su_docs/aces/fr-cont.html

-------------------------------------------------------------------------

[Federal Register: November 9, 2001 (Volume 66, Number 218)]
[Notices]
[Page 56659-56660]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09no01-53]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning Method of Treating,
Preventing or Inhibiting Central Nervous System (CNS) Injuries and
Diseases

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability for licensing of U.S. Patent Application No. 09/839,905
entitled ``Method of Treating, Preventing or Inhibiting Central Nervous
System Injuries and Diseases'' and filed 20 April 2001. Foreign rights
are also available (PCT/US01/13043). The United States Government, as
represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
Attn.: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research & Technology Assessment, (301) 619-5034. Both
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Method of preventing, treating or both
preventing and treating CNS injury, disease, neurotoxicity or memory
deficit in a subject by the administration of at least one lipoic acid
compound to the subject are disclosed. Examples of CNS injuries or
disease include traumatic brain injury (TBI), posttraumatic epilepsy
(PTE), stroke, cerebral ischemia, neuorodegenerative diseases of the
brain such as Parkinson's Disease, Dementia Pugilisitica, Huntington's
disease and Alzheimer's disease, brain injuries secondary to seizures
which are induced by radiation, exposure to ionizing or iron plasma,
nerve agents, cyanide, toxic concentrations of oxygen, neurotoxicity
due to CNS malaria or treatment with antimalaria agents, and other CNS
traumas. Examples of lipoic acid compounds include -lipoic
acid (-LA), dihydrolipoic acid (DHLA), 2-(N,N-dimethylamine)
ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-
isomers thereof, the metabolites of -lipoic acid such as 6,8-
bisnorlipoic acid and tetranorlipoic acid

[[Page 56660]]

and analogs thereof. Also disclosed are pharmaceutical compositions and
kits comprising at least one lipoic acid compound.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 01-28243 Filed 11-8-01; 8:45 am]
BILLING CODE 3710-08-M